End-of-day quote
Taipei Exchange
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
195
TWD
|
+4.28%
|
|
+8.33%
|
+9.72%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,656
|
9,043
|
9,856
|
13,013
|
15,025
|
14,338
|
Enterprise Value (EV)
1 |
4,858
|
8,485
|
9,484
|
11,703
|
13,773
|
13,009
|
P/E ratio
|
-77.1
x
|
-96
x
|
-92.1
x
|
35.4
x
|
75.3
x
|
27.1
x
|
Yield
|
-
|
-
|
-
|
2.38%
|
0.9%
|
3.07%
|
Capitalization / Revenue
|
-
|
835,884,999
x
|
139,609,330
x
|
29,652,400
x
|
23,943,663
x
|
18,905,448
x
|
EV / Revenue
|
-
|
784,288,825
x
|
134,343,228
x
|
26,668,891
x
|
21,948,957
x
|
17,152,867
x
|
EV / EBITDA
|
-55.7
x
|
-68.8
x
|
-69.9
x
|
82.7
x
|
44.8
x
|
36.4
x
|
EV / FCF
|
-70.7
x
|
-100
x
|
-64
x
|
117
x
|
62.7
x
|
42.7
x
|
FCF Yield
|
-1.41%
|
-1%
|
-1.56%
|
0.86%
|
1.59%
|
2.34%
|
Price to Book
|
6.07
x
|
10.7
x
|
12.7
x
|
6.86
x
|
8.38
x
|
7.78
x
|
Nbr of stocks (in thousands)
|
74,512
|
74,512
|
74,512
|
82,254
|
82,424
|
80,673
|
Reference price
2 |
75.91
|
121.4
|
132.3
|
158.2
|
182.3
|
177.7
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
10.82
|
70.6
|
438.8
|
627.5
|
758.4
|
EBITDA
1 |
-87.23
|
-123.4
|
-135.6
|
141.5
|
307.3
|
357.7
|
EBIT
1 |
-93.77
|
-135.5
|
-157.1
|
116.2
|
283.8
|
337.7
|
Operating Margin
|
-
|
-1,252.31%
|
-222.54%
|
26.48%
|
45.23%
|
44.53%
|
Earnings before Tax (EBT)
1 |
-87.02
|
-119.6
|
-137.4
|
396.8
|
264.1
|
623
|
Net income
1 |
-68.77
|
-94.22
|
-106.8
|
369.6
|
200.7
|
539.4
|
Net margin
|
-
|
-870.87%
|
-151.32%
|
84.22%
|
31.99%
|
71.12%
|
EPS
2 |
-0.9845
|
-1.264
|
-1.435
|
4.464
|
2.422
|
6.564
|
Free Cash Flow
1 |
-68.69
|
-84.78
|
-148.1
|
100.3
|
219.6
|
304.5
|
FCF margin
|
-
|
-783.66%
|
-209.76%
|
22.86%
|
35%
|
40.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
70.91%
|
71.47%
|
85.12%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
27.14%
|
109.41%
|
56.45%
|
Dividend per Share
|
-
|
-
|
-
|
3.758
|
1.648
|
5.454
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
155.1
|
123.5
|
152.6
|
-
|
179.7
|
116.9
|
159.7
|
226.8
|
112.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
60.36
|
49.34
|
61.49
|
-
|
98.09
|
23.99
|
62.14
|
117.7
|
63.59
|
Operating Margin
|
38.92%
|
39.95%
|
40.29%
|
-
|
54.57%
|
20.53%
|
38.91%
|
51.89%
|
56.63%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
38.24
|
-
|
-
|
-
|
-
|
98.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
87.36%
|
EPS
2 |
-
|
-
|
-
|
0.4630
|
-
|
-
|
-
|
-
|
1.218
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/12/22
|
8/12/22
|
11/11/22
|
3/30/23
|
5/15/23
|
8/11/23
|
11/14/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
798
|
558
|
372
|
1,309
|
1,252
|
1,329
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-68.7
|
-84.8
|
-148
|
100
|
220
|
304
|
ROE (net income / shareholders' equity)
|
-10.7%
|
-10.6%
|
-13.1%
|
27.6%
|
10.9%
|
29.7%
|
ROA (Net income/ Total Assets)
|
-9%
|
-9.12%
|
-11.1%
|
5.04%
|
8.88%
|
10.4%
|
Assets
1 |
764
|
1,033
|
962.4
|
7,331
|
2,261
|
5,174
|
Book Value Per Share
2 |
12.50
|
11.40
|
10.40
|
23.10
|
21.70
|
22.80
|
Cash Flow per Share
2 |
0.1800
|
0.4300
|
0.9200
|
7.790
|
4.290
|
4.170
|
Capex
1 |
20.6
|
5.36
|
58.8
|
1.98
|
3.19
|
5.82
|
Capex / Sales
|
-
|
49.58%
|
83.33%
|
0.45%
|
0.51%
|
0.77%
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| +9.72% | 484M | | -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B |
Biopharmaceuticals
|